<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02728193</url>
  </required_header>
  <id_info>
    <org_study_id>2012ZX10002016003001</org_study_id>
    <nct_id>NCT02728193</nct_id>
  </id_info>
  <brief_title>Standard Treatments of Very-early Stage Hepatocellular Carcinoma</brief_title>
  <official_title>The Research on Standard Treatments of Very-early Stage Hepatocellular Carcinoma: a Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eastern Hepatobiliary Surgery Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eastern Hepatobiliary Surgery Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of our study was to elucidate the difference in the rates of complication,
      hospitalization days, medical expenses, MRI showed that the degree of tumor necrosis, and
      overall survival rates of the therapies between PEI, MVA and RFA, and make the standard for
      minimally invasive treatment of very early stage HCC.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrence</measure>
    <time_frame>3 years</time_frame>
    <description>Hepatocellular Carcinoma will recurrence in 3 years</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Death</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">300</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <condition>Very-early Stage</condition>
  <arm_group>
    <arm_group_label>RFA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radiofrequency ablation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MWV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Microwave ablation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PEI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Percutaneous ethanol injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>RFA</intervention_name>
    <arm_group_label>RFA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>MWV</intervention_name>
    <arm_group_label>MWV</arm_group_label>
    <other_name>Microwave ablation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>PEI</intervention_name>
    <description>Percutaneous ethanol injection</description>
    <arm_group_label>PEI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Preoperative clinical, imaging and tumor markers were diagnosed as hepatocellular
             carcinoma

          2. Tumor diameter&lt;2cm

          3. Child-Pugh class A liver function

          4. Without major organ dysfunction

          5. male or female patients &gt; 18 years and &lt;=70 years of age

          6. Voluntary participation in this clinical trial

        Exclusion Criteria:

          1. Other anticancer treatment before therapy

          2. Patients with apparent major organs (i.e. cardiac, pulmonary, cerebral and renal)
             dysfunction, which may affect the treatment of liver cancer

          3. Patients with other diseases that may affect the treatment of this treatment

          4. History of other malignant tumors

          5. Patients who are participating in other clinical trials

          6. Pregnant, lactating women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Eastern hepatobilliary surgery hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200438</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 28, 2016</study_first_submitted>
  <study_first_submitted_qc>March 30, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 5, 2016</study_first_posted>
  <last_update_submitted>March 30, 2016</last_update_submitted>
  <last_update_submitted_qc>March 30, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Eastern Hepatobiliary Surgery Hospital</investigator_affiliation>
    <investigator_full_name>ShenFeng</investigator_full_name>
    <investigator_title>vice president of the Eastern Hepatobiliary Surgery Hospotal</investigator_title>
  </responsible_party>
  <keyword>treatments</keyword>
  <keyword>hepatocellular carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

